Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2017-08-03 Declaration of Voting R…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
FORM 6-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It announces the results of the Annual General Meeting (AGM) held on August 3, 2017, including shareholder approvals of various proposals such as re-appointment of auditors, election of directors, increase in authorized share capital, CEO employment terms, and compensation policy. The content is focused on reporting the outcomes of the AGM rather than providing the full AGM materials or presentations. The document is about the announcement of voting results at the AGM, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6921 characters) and content confirm it is not merely a brief announcement or a full report but a detailed voting results announcement. Therefore, the appropriate classification is DVA with high confidence.
2017-08-03 English
Immediate Report of Meeting
AGM Information Classification · 98% confidence The document explicitly states it is an "Immediate Report of Meeting" concerning the "postponement of meeting" for an "annual meeting" scheduled for 03/08/2017. It details the agenda items, which include re-electing directors and approving an increase in share capital, all of which are typical matters discussed at an Annual General Meeting (AGM). Furthermore, the document is a regulatory filing notice to the Israel Securities Authority and the Tel Aviv Stock Exchange, indicating it is an official announcement related to the AGM proceedings, specifically the postponement and the agenda items to be voted upon. Since it details the agenda and the postponement of the AGM, it is most closely related to AGM Information (AGM-R). While it is a notice, the content is substantive regarding the AGM itself, making AGM-R more specific than a general RPA or RNS.
2017-07-27 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, XTL Biopharmaceuticals Ltd., submitted to the SEC. It announces the postponement of the annual shareholders' meeting due to lack of quorum and provides details about the rescheduled meeting date. The document does not contain financial statements or detailed financial analysis but is an announcement related to corporate governance and shareholder meeting scheduling. It is not a full annual report, interim report, or earnings release. The content aligns with a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like AGM Information or Declaration of Voting Results. The document length is 5488 characters, which is sufficient for a substantive announcement but does not contain financial data or meeting materials themselves. Therefore, the best classification is Regulatory Filings (RNS).
2017-07-27 English
Other Report or Announcement
Board/Management Information Classification · 95% confidence The document is explicitly titled "FORM 6-K" and is filed by a Foreign Private Issuer for the month of July 2017. The content discusses the automatic expiration of an external director's term (Gil Oren) and mentions that Yaacov Goldman is standing for election at the upcoming 2017 Annual General Meeting (AGM). Since the core subject matter relates to changes in the board of directors and upcoming shareholder voting matters, it touches upon Board/Management Information (MANG) and potentially AGM/Proxy information. However, Form 6-K is a general reporting mechanism for foreign private issuers to report material information not otherwise required to be reported on a schedule. The most specific and actionable information provided here is the change in director status and the context for the upcoming AGM election. Given the explicit mention of director term expiration and the nomination of a replacement director, the most fitting category is Board/Management Information (MANG). While it mentions the AGM, the focus is on the director change itself, not the voting results (DVA) or the proxy materials (PSI).
2017-07-10 English
Other Report or Announcement
Board/Management Information Classification · 95% confidence The document is a filing reported via MAGNA to the Israel Securities Authority and the Tel Aviv Stock Exchange. The content discusses the automatic expiration of an external director's term (Gil Oren) and the nomination of a replacement (Yaacov Goldman) to be voted upon at the upcoming 2017 Annual General Meeting (AGM). The text explicitly mentions the planned AGM on July 25, 2017, where a director election will take place. This relates directly to the governance and management structure of the company, specifically concerning board composition and upcoming shareholder votes. Since the document is an announcement regarding director changes and an upcoming vote, it most closely aligns with Board/Management Information (MANG) or potentially Governance Information (CGR). However, the core subject is the change in director status and the election process, which fits best under Board/Management Information (MANG) as it details changes in senior personnel/board members. It is not a full AGM presentation (AGM-R), a proxy statement (PSI), or a general earnings release (ER). Given the focus on director tenure and replacement, MANG is the most appropriate classification.
2017-07-10 English
Immediate Report of Meeting
AGM Information Classification · 98% confidence The document is explicitly titled 'FORM 6-K' and is filed 'For the Month of June 2017'. A Form 6-K is a report of a Foreign Private Issuer, which often contains material information that is not required to be filed on a regular basis in the US. The content details the announcement of an 'Annual General Meeting of Shareholders' scheduled for July 27, 2017, and explicitly furnishes the 'Notice and Proxy Statement' (Exhibit 99.1) and proxy cards. Since the core purpose of this 6-K filing is to distribute the official notice and proxy materials for the upcoming AGM, the most specific classification is AGM-R (AGM Information). Although it contains proxy materials (which might suggest DEF 14A or PSI), the context is the official distribution of the AGM notice itself via a Form 6-K, making AGM-R the best fit for the meeting materials being announced/filed.
2017-06-22 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.